Search This Blog

Thursday, December 21, 2023

Alpine Amends Acazicolcept Option and License Agreement with AbbVie

 -- Enrollment in the phase 2 study of acazicolcept in systemic lupus erythematosus (Synergy) will be stopped to allow for early assessment of data --

-- Final analysis after last patient completes study protocol expected to occur by the end of 2024 --

https://www.businesswire.com/news/home/20231221900461/en/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.